NRIX Nurix Therapeutics Inc revenue, earnings and financials
For the quarter ended August 31, 2026, Nurix Therapeutics Inc reported revenue of $673M (up 8426.3% from a year earlier), net income of $550M and diluted EPS of $4.73; over the last four quarters revenue was $702M and net income $295M; for the fiscal year ended November 2025 revenue was $84.0M, up 54.0% on the year before.
NRIX annual revenue and earnings
- Fiscal year ended Nov 2025: revenue $84.0M, gross profit n/a, operating income −$286M, net income −$264M (margin -314.9%), EPS −$3.05
- Fiscal year ended Nov 2024: revenue $54.5M, gross profit n/a, operating income −$213M, net income −$194M (margin -354.9%), EPS −$2.88
- Fiscal year ended Nov 2023: revenue $77.0M, gross profit n/a, operating income −$155M, net income −$144M (margin -187.0%), EPS −$2.65
- Fiscal year ended Nov 2022: revenue $38.6M, gross profit n/a, operating income −$184M, net income −$180M (margin -466.9%), EPS −$3.71
- Fiscal year ended Nov 2021: revenue $29.8M, gross profit n/a, operating income −$118M, net income −$117M (margin -393.9%), EPS −$2.73
NRIX quarterly revenue and earnings
- Quarter ended Aug 31, 2026: revenue $673M (up 8426.3% year over year), net income $550M, EPS $4.73
- Quarter ended May 31, 2026: revenue $9.04M (down 79.5% year over year), net income −$89.5M, EPS −$0.81
- Quarter ended Feb 28, 2026: revenue $6.25M (down 66.1% year over year), net income −$87.2M, EPS −$0.79
- Quarter ended Nov 30, 2025 (from the annual report): revenue $13.6M (up 2.2% year over year), net income −$78.2M, EPS −$0.83
- Quarter ended Aug 31, 2025: revenue $7.89M (down 37.3% year over year), net income −$86.4M, EPS −$1.03
- Quarter ended May 31, 2025: revenue $44.1M (up 264.3% year over year), net income −$43.5M, EPS −$0.52
- Quarter ended Feb 28, 2025: revenue $18.5M (up 11.3% year over year), net income −$56.4M, EPS −$0.67
- Quarter ended Nov 30, 2024 (from the annual report): revenue $13.3M (down 12.4% year over year), net income −$58.5M, EPS −$0.74
- Quarter ended Aug 31, 2024: revenue $12.6M (down 31.8% year over year), net income −$49.0M, EPS −$0.67
- Quarter ended May 31, 2024: revenue $12.1M (down 60.6% year over year), net income −$44.5M, EPS −$0.71
- Quarter ended Feb 29, 2024: revenue $16.6M (up 30.7% year over year), net income −$41.5M, EPS −$0.76
- Quarter ended Nov 30, 2023 (from the annual report): revenue $15.2M (up 123.5% year over year), net income −$42.0M, EPS −$0.77
- Quarter ended Aug 31, 2023: revenue $18.5M (up 71.1% year over year), net income −$37.0M, EPS −$0.68
- Quarter ended May 31, 2023: revenue $30.7M (up 168.3% year over year), net income −$24.3M, EPS −$0.45
- Quarter ended Feb 28, 2023: revenue $12.7M (up 31.8% year over year), net income −$40.7M, EPS −$0.75
- Quarter ended Nov 30, 2022 (from the annual report): revenue $6.78M (down 8.3% year over year), net income −$46.7M, EPS −$0.85
- Quarter ended Aug 31, 2022: revenue $10.8M (up 5.3% year over year), net income −$45.7M, EPS −$0.90
- Quarter ended May 31, 2022: revenue $11.4M (up 61.2% year over year), net income −$45.4M, EPS −$1.01
- Quarter ended Feb 28, 2022: revenue $9.62M (up 92.0% year over year), net income −$42.5M, EPS −$0.95
- Quarter ended Nov 30, 2021 (from the annual report): revenue $7.40M, net income −$37.7M, EPS −$0.85
NRIX cash flow, buybacks and dividends
- Fiscal year ended Nov 2025: operating cash flow −$249M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Nov 2024: operating cash flow −$173M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Nov 2023: operating cash flow −$81.4M, share buybacks n/a
- Fiscal year ended Nov 2022: operating cash flow −$160M, share buybacks n/a
- Fiscal year ended Nov 2021: operating cash flow −$84.4M, share buybacks n/a
NRIX balance sheet
- Aug 31, 2026: cash $720M, total assets $1.20B, total liabilities $227M, shareholders' equity $968M
- May 31, 2026: cash $67.7M, total assets $536M, total liabilities $133M, shareholders' equity $403M
- Feb 28, 2026: cash $71.2M, total assets $636M, total liabilities $155M, shareholders' equity $481M
- Nov 30, 2025: cash $247M, total assets $688M, total liabilities $149M, shareholders' equity $539M
- Aug 31, 2025: cash $78.4M, total assets $522M, total liabilities $150M, shareholders' equity $372M
- May 31, 2025: cash $84.3M, total assets $592M, total liabilities $144M, shareholders' equity $448M
- Feb 28, 2025: cash $75.9M, total assets $615M, total liabilities $134M, shareholders' equity $481M
- Nov 30, 2024: cash $110M, total assets $669M, total liabilities $142M, shareholders' equity $527M
What is NRIX's revenue?
Nurix Therapeutics Inc reported $702M of revenue over its last four quarters, through August 31, 2026.
Is NRIX profitable?
Yes. Nurix Therapeutics Inc earned $295M over the last four quarters.
What is NRIX's EPS?
Diluted earnings per share over the last four quarters were $2.30; $4.73 in the latest quarter.